Investigational · not FDA approved

Editorially reviewed · Last updated February 2026 · How we review

Retatrutide vs Wegovy: Triple Agonist vs GLP-1

Key findings

Retatrutide has produced greater average weight loss in separate trials, while Wegovy is available now with years of use and proven cardiovascular benefit.
Retatrutide activates GLP-1, GIP, and glucagon receptors; semaglutide activates GLP-1 alone.
The often-quoted 28.7% versus 14.9% figures come from different trials, not a direct retatrutide-versus-Wegovy study.
Wegovy is FDA-approved; retatrutide remains investigational and still needs longer-term outcomes data.

Retatrutide vs Wegovy: Triple Agonist vs GLP-1

Retatrutide produces nearly double the weight loss of Wegovy (28.7% vs 14.9%), but Wegovy has major advantages: it is available now in both injectable and oral form, has proven cardiovascular protection (the SELECT trial), and has over 5 years of real-world safety data.

Side-by-Side Comparison

	Retatrutide	Wegovy (Semaglutide)
Mechanism	Triple agonist: GLP-1 + GIP + Glucagon	GLP-1 receptor agonist only
Manufacturer	Eli Lilly	Novo Nordisk
Max weight loss	-28.7% at 68 weeks (TRIUMPH-4, 12 mg)	-14.9% at 68 weeks (STEP 1, 2.4 mg)
Administration	Once-weekly injection	Once-weekly injection OR daily oral pill
Oral option	None	Yes — Wegovy oral approved Dec 2025
FDA status	Not approved (Phase 3)	Approved (June 2021)
CV outcomes	Trial ongoing (TRIUMPH CVOT)	20% MACE reduction proven (SELECT)
Discontinuation (AEs)	18.2% (12 mg)	7.0%
Dysesthesia	20.9% at 12 mg	Not observed
Monthly cost	Not yet available (~$1,200–1,500 projected)	$1,349 injectable; $149–299 oral (cash)

How the Mechanisms Differ

Wegovy (semaglutide) targets the GLP-1 receptor only. It suppresses appetite through hypothalamic signaling, slows gastric emptying, enhances insulin secretion, and reduces glucagon release. It works primarily by reducing how much you eat.

Retatrutide adds GIP and glucagon receptor activation on top of GLP-1. The glucagon component increases resting energy expenditure through thermogenesis and promotes liver fat oxidation. Retatrutide works by reducing intake and increasing expenditure — both sides of the energy equation.

This mechanism difference explains the nearly 2x weight loss gap. For details, see How Does Retatrutide Work?.

Weight Loss Comparison

Drug	Trial	Duration	Weight Loss
Retatrutide 12 mg	TRIUMPH-4 (Phase 3)	68 weeks	-28.7%
Retatrutide 9 mg	TRIUMPH-4 (Phase 3)	68 weeks	-26.4%
Semaglutide 2.4 mg	STEP 1	68 weeks	-14.9%
Semaglutide 2.4 mg	STEP 3 (+ behavioral therapy)	68 weeks	-16.0%
Semaglutide 7.2 mg (investigational)	STEP UP	72 weeks	-20.7%

Weight Loss Thresholds

Threshold	Retatrutide 12 mg	Wegovy 2.4 mg
Lost at least 15%	83.2%	48.9%
Lost at least 20%	72.5%	35.5%
Lost at least 25%	58.6%	13.2%

For a 250-lb person: retatrutide produces approximately 35 more pounds of weight loss than Wegovy (~72 lbs vs ~37 lbs).

Cardiovascular Protection: Wegovy's Advantage

Wegovy has a proven cardiovascular benefit that retatrutide does not yet have:

The SELECT Trial — a landmark study showing semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with heart disease and obesity. This led to an expanded FDA indication for cardiovascular risk reduction and potential Medicare coverage.

Retatrutide's TRIUMPH CVOT is ongoing, with results expected in 2027-2028. Early blood pressure data is promising (retatrutide reduced systolic BP by -14.0 mmHg vs semaglutide's approximately -6 mmHg), but this has not been confirmed in a dedicated outcomes trial.

Wegovy's Oral Formulation

In December 2025, the FDA approved oral Wegovy (semaglutide 25 mg tablet) — the first oral GLP-1 for weight loss. This eliminates the injection barrier:

Efficacy: 16.6% average weight loss (comparable to injectable Wegovy)
Cash price: $149-299/month through telehealth providers
No fasting required (unlike older oral semaglutide Rybelsus)
One-third of participants lost 20%+ body weight

Retatrutide has no oral formulation in development. It is a peptide that requires injection.

Side Effects Comparison

	Retatrutide 12 mg	Wegovy 2.4 mg
Nausea	43%	44%
Diarrhea	33%	30%
Vomiting	21%	24%
Discontinuation (AEs)	18.2%	7.0%
Dysesthesia	20.9%	Not observed

GI side effects are broadly similar. However, retatrutide has a notably higher discontinuation rate (18.2% vs 7.0%) and a unique dysesthesia signal (tingling/burning sensations) not seen with semaglutide.

Wegovy's advantage: over 5 years of real-world safety data from millions of patients, compared to retatrutide's trial-only experience.

Frequently Asked Questions

Is retatrutide better than Wegovy?

Retatrutide produces nearly double the weight loss (28.7% vs 14.9%). However, Wegovy is available now, has proven cardiovascular protection, an oral formulation, and lower discontinuation rates. "Better" depends on individual needs — maximum weight loss vs availability and proven safety.

Should I wait for retatrutide or start Wegovy now?

If you qualify for Wegovy (or Zepbound/Mounjaro), starting treatment now is reasonable. Retatrutide won't be available until late 2027 at the earliest. Talk to your doctor about currently approved options. See When Will Retatrutide Be Available?.

Can I switch from Wegovy to retatrutide later?

No studies have examined switching from semaglutide to retatrutide. If retatrutide is approved, your doctor could potentially transition you, but switching protocols have not been established.

Sources

Jastreboff, A.M., et al. (2021). Semaglutide 2.4 mg for the Treatment of Obesity (STEP 1). NEJM. DOI: 10.1056/NEJMoa2032183.
Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. DOI: 10.1056/NEJMoa2307563.
Eli Lilly. (2025). TRIUMPH-4 results. Press release.
Novo Nordisk. (2025). Wegovy Oral FDA Approval. Press release.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources